Cheolwon Suh

13.1k total citations
413 papers, 7.8k citations indexed

About

Cheolwon Suh is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Cheolwon Suh has authored 413 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 260 papers in Pathology and Forensic Medicine, 249 papers in Oncology and 84 papers in Genetics. Recurrent topics in Cheolwon Suh's work include Lymphoma Diagnosis and Treatment (254 papers), Viral-associated cancers and disorders (116 papers) and CNS Lymphoma Diagnosis and Treatment (74 papers). Cheolwon Suh is often cited by papers focused on Lymphoma Diagnosis and Treatment (254 papers), Viral-associated cancers and disorders (116 papers) and CNS Lymphoma Diagnosis and Treatment (74 papers). Cheolwon Suh collaborates with scholars based in South Korea, United States and Japan. Cheolwon Suh's co-authors include Dok Hyun Yoon, Jooryung Huh, Won Seog Kim, Dae Ho Lee, Seok Jin Kim, Jin Seok Kim, Young Wha Koh, Young Hyeh Ko, Chan-Sik Park and Kihyun Kım and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Cheolwon Suh

392 papers receiving 7.7k citations

Peers

Countries citing papers authored by Cheolwon Suh

Since Specialization

Citations

This map shows the geographic impact of Cheolwon Suh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheolwon Suh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheolwon Suh more than expected).

Fields of papers citing papers by Cheolwon Suh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheolwon Suh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheolwon Suh. The network helps show where Cheolwon Suh may publish in the future.

Co-authorship network of co-authors of Cheolwon Suh

This figure shows the co-authorship network connecting the top 25 collaborators of Cheolwon Suh. A scholar is included among the top collaborators of Cheolwon Suh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheolwon Suh. Cheolwon Suh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma 2021 ·Journal of Clinical Medicine ·Mi Hyun Bae, Chan‐Jeoung Park, Cheolwon Suh	13
2	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma 2020 ·Bone Marrow Transplantation ·Ga‐Young Song, Dok Hyun Yoon, Cheolwon Suh, Joon Ho Moon, Dong Won Baek, Jin Seok Kim, Gyeong‐Won Lee, Jun Ho Yi, Yong Park, Ki Sun Jung, Seok Jin Kim, Deok‐Hwan Yang, Won Seog Kim	10
3	Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma 2020 ·Annals of Laboratory Medicine ·Min Young Lee, Chan‐Jeoung Park, Young‐Uk Cho, (unknown), Seongsoo Jang, Eul‐Ju Seo, Jung‐Hee Lee, Dok Hyun Yoon, Cheolwon Suh	3
4	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma 2019 ·BMC Cancer ·Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho‐Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung‐Sook Lee, Kengo Takeuchi, Dong‐Yeop Shin, Cheolwon Suh, Won Seog Kim	20
5	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial) 2019 ·Leukemia & lymphoma ·(unknown), Won Seog Kim, Cheolwon Suh, Jung Yong Hong, Deok‐Hwan Yang, Won Sik Lee, Young Rok, Young‐Il Koh, Jong-Ho Won, Min Kyoung Kim, Jae‐Cheol Jo, Shin Young Hyun, Jeong‐A Kim, Young‐Ha Oh, Seung‐Sook Lee	4
6	Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia 2019 ·Annals of Laboratory Medicine ·(unknown), Chan‐Jeoung Park, Young‐Uk Cho, Seongsoo Jang, Eul‐Ju Seo, Jung‐Hee Lee, Dok Hyun Yoon, Cheolwon Suh	4
7	Geological Models of Platinum Group Elements (PGE) Depletion in Metamorphosed Ultramafic Rocks of the Nyong Series, Southeast Cameroon 2017 ·(unknown), Akumbom Vishiti, Cheolwon Suh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
8	Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL 2017 ·Blood ·(unknown), Cheolwon Suh, Jae Joon Kim, Jung Yong Hong	2
9	Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma 2017 ·Blood ·Min Young Lee, Chan‐Jeoung Park, Young‐Uk Cho, (unknown), Seongsoo Jang, Jung‐Hee Lee, Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh	2
10	RGS1 expression is associated with poor prognosis in multiple myeloma 2016 ·Journal of Clinical Pathology ·Jin Roh, Su‐Jin Shin, (unknown), Dok Hyun Yoon, Cheolwon Suh, Chan‐Jeoung Park, Jooryung Huh, Chan-Sik Park	29
11	A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas 2016 ·Annals of Oncology ·Seung Ju Kim, (unknown), Jin Sung Kim, Dok Hyun Yoon, (unknown), (unknown), Young-Rok Do, Hye Jin Kang, Hyeon‐Seok Eom, Young Hyeh Ko, S.H. Lee, Hae Young Yoo, Min Eui Hong, Cheolwon Suh, Woo Seob Kim	39
12	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial 2015 ·Leukemia & lymphoma ·Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Yee Soo Chae, Gyeong‐Won Lee, Hyeon Seok Eom, Hun Mo Ryoo, Suee Lee, Seok Jin Kim, Dok Hyun Yoon, Jong-Ho Won, Junshik Hong, Jinny Park, Sang Min Lee, Jung Yong Hong, Eunkyung Park, Hyo Jung Kim, Deok‐Hwan Yang, Hyo-Jin Kim, Cheolwon Suh	4
13	Cytogenetic classification in K orean multiple myeloma patients: prognostic significance of hyperdiploidy with 47–50 chromosomes and the number of structural abnormalities 2013 ·European Journal Of Haematology ·Ji‐Hun Lim, Eul‐Ju Seo, Chan‐Jeoung Park, Seongsoo Jang, Hyun‐Sook Chi, Cheolwon Suh, Hawk Kim, Sung‐Ryul Kim	13
14	FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy 2011 ·Clinical Cancer Research ·Dok Hyun Yoon, Sora Baek, Chang‐Min Choi, Dae Ho Lee, Cheolwon Suh, Jin‐Sook Ryu, Dae Hyuk Moon, Jung Shin Lee, Sang-We Kim	13
15	Primary gastrointestinal diffuse large B-cell lymphoma: A clinical analysis of 76 patients with special application of International Prognostic Index for survival 2007 ·The Korean Journal of Internal Medicine ·Ja Eun Koo, (unknown), Danbi Lee, Eun Hee Kim, (unknown), Shin Kim, (unknown), Yoon‐Koo Kang, Jooryung Huh, Cheolwon Suh	0
16	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients. 2007 ·Blood ·Seok Jin Kim, Hyo Jin Lee, Hawk Kim, Kihyun Kım, Jae‐Yong Kwak, (unknown), Jung Hye Kwon, Sang Kyun Sohn, Jong-Ho Won, Jae Hoon Lee, Cheolwon Suh, Sung‐Soo Yoon, Yongjun Cha, (unknown), (unknown), Inho Kim, Young-Rok Do, Won-Sik Lee, Young‐Don Joo, Hyo Jung Kim, (unknown)	0
17	Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study 2007 ·Annals of Oncology ·D.H. Lee, (unknown), Cheolwon Suh, (unknown), (unknown), Jeong Hyun Lee, (unknown), Baek‐Yeol Ryoo, K. Park, (unknown), Dae Seog Heo, (unknown)	42
18	Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non–small-cell lung cancer 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Young Seok Kim, Sang Min Yoon, Eun Kyung Choi, Byong Yong Yi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Seong Soo Shin, Jung Shin Lee, Cheolwon Suh, Sang‐We Kim, (unknown), Woo Sung Kim, Heon Joo Park, Charn Il Park	31
19	Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia 2003 ·Blood Research ·Hee-Jung Sohn, (unknown), (unknown), (unknown), (unknown), Eun-Kyung Kim, Gyeong‐Won Lee, Jae‐Lyun Lee, Min‐Hee Ryu, Seong‐Jun Choi, Je‐Hwan Lee, Sung‐Bae Kim, Sang‐We Kim, Kyoo‐Hyung Lee, Jung‐Shin Lee, Woo-Kun Kim, Cheolwon Suh	0
20	소장 및 대장에서 발생한 원발성 장 림프종 2003 ·Journal of the Korean Surgical Society ·(unknown), (unknown), Jooryung Huh, (unknown), Cheolwon Suh, (unknown), Yoon‐Koo Kang, (unknown), (unknown), Jin-Chun Kim	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact